StockNews.com Upgrades Adverum Biotechnologies (NASDAQ:ADVM) to Hold

Adverum Biotechnologies (NASDAQ:ADVM – Get Free Report) was upgraded by research analysts at StockNews.com from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Friday. A number of other research firms also recently weighed in on ADVM. Chardan Capital reissued a “buy” rating and set a $4.00 […]

Related Keywords

United States ,America ,James Paul Scopa ,Adverum Biotechnologies Inc ,Vr Adviser ,America Corp ,Capital Management ,Securities Exchange Commission ,Nasdaq ,Adverum Biotechnologies ,Get Free Report ,Director James Paul Scopa ,Exchange Commission ,Adverum Biotechnologies Daily ,